Cargando…
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed wit...
Autores principales: | Serzan, Michael T, Kumar, Princy N, Atkins, Michael B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246106/ https://www.ncbi.nlm.nih.gov/pubmed/32434789 http://dx.doi.org/10.1136/jitc-2020-000898 |
Ejemplares similares
-
Immunosuppressants/oseltamivir: Coronavirus HKU1 infection and development of resistance: case report
Publicado: (2020) -
Coronavirus-HKU1 Pneumonia and Differential Diagnosis with COVID-19
por: Pianura, Elisa, et al.
Publicado: (2020) -
More and More Coronaviruses: Human Coronavirus HKU1
por: Woo, Patrick C. Y., et al.
Publicado: (2009) -
Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020) -
Coronavirus HKU1 in Children, Brazil, 1995
por: Góes, Luiz G., et al.
Publicado: (2011)